Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 9005-27-0
2. Starch, 2-hydroxyethyl Ether
3. 2-hydroxyethyl Starch
4. (2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;2-[[(2r,3r,4s,5r,6s)-3,4,5,6-tetrakis(2-hydroxyethoxy)oxan-2-yl]methoxy]ethanol
5. Hydroxyethyl Starch 130/0.4
6. Starch, 2-hydroxyethyl Ether, Base-hydrolyzed
7. 68512-26-5
8. Chembl1730764
9. Akos030254900
10. Hydroxyethyl Starch (high Mw), European Pharmacopoeia (ep) Reference Standard
11. Hydroxyethyl Starch (medium Mw), European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 580.6 g/mol |
|---|---|
| Molecular Formula | C22H44O17 |
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 17 |
| Exact Mass | 580.25784993 g/mol |
| Monoisotopic Mass | 580.25784993 g/mol |
| Topological Polar Surface Area | 267 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 497 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.
After isovolemic exchange of blood with 500 mL of HES in healthy volunteers, blood volume is maintained for at least 6 hours
Absorption
Peak concentration (C(max), 4.34 mg/mL)
Route of Elimination
Approximately 62 % of HES was excreted as hydroxyethyl starch molecules in urine within 72 hours.
Volume of Distribution
5.9 L.
Clearance
31.4 mL/min
When given intravenously, molecules smaller than the renal threshold (60,000-70,000 daltons) are readily and rapidly excreted in the urine, while molecules with higher molecular weights are metabolized by plasma -amylase prior to excretion via the renal route.
Terminal half-life is 16.1 h. Elimination half-life is 12 h.
Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. Recent studies have indicated that HES may reduce capillary leakage.
SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.
Certificate Number : R1-CEP 2014-317 - Rev 00
Issue Date : 2021-09-10
Type : Chemical
Substance Number : 1785
Status : Valid


Registrant Name : Fresenius Kabi Korea Co., Ltd.
Registration Date : 2022-06-22
Registration Number : 20220622-210-J-1318
Manufacturer Name : Fresenius Kabi Austria GmbH
Manufacturer Address : Estermannstraße 17, 4020 Linz, Austria

Certificate Number : R1-CEP 2014-107 - Rev 00
Issue Date : 2020-04-09
Type : Chemical
Substance Number : 1785
Status : Valid

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Starches, Hydroxyethyl, Mw 130, MS 0.4, C2/C6 6
Certificate Number : R1-CEP 2014-107 - Rev 00
Status : Valid
Issue Date : 2020-04-09
Type : Chemical
Substance Number : 1785

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Starches, Hydroxyethyl, Mw 130, MS 0.4, C2/C6 9
Certificate Number : R1-CEP 2014-317 - Rev 00
Status : Valid
Issue Date : 2021-09-10
Type : Chemical
Substance Number : 1785

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.
About the Company : Swati Spentose Pvt. Ltd. (SSPL), part of the 60-year-old V Group, is a globally trusted pharmaceutical manufacturer supplying to 70+ countries. We specialize in high-quality APIs a...
About the Company : Shandong Qidu Pharmaceutical is a comprehensive and research-based drug production enterprise which produces IV solutions, oral preparations, APIs and so on. The products mainly in...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Volulyte (Hydroxyethyl Starch) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.
Lead Product(s): Hydroxyethyl Starch,Inapplicable
Therapeutic Area: Hematology Brand Name: Volulyte
Study Phase: Phase IVProduct Type: Carbohydrate
Sponsor: B. Braun Medical | European Society of Anaesthesiology and Intensive Care
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxyethyl Starch,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : B. Braun Medical | European Society of Anaesthesiology and Intensive Care
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Volulyte (Hydroxyethyl Starch) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.
Product Name : Volulyte
Product Type : Carbohydrate
Upfront Cash : Inapplicable
November 09, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Volulyte (Hydroxyethyl Starch) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.
Lead Product(s): Hydroxyethyl Starch,Inapplicable
Therapeutic Area: Hematology Brand Name: Volulyte
Study Phase: Phase IVProduct Type: Carbohydrate
Sponsor: B. Braun Medical | European Society of Anaesthesiology and Intensive Care
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxyethyl Starch,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : B. Braun Medical | European Society of Anaesthesiology and Intensive Care
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Volulyte (Hydroxyethyl Starch) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.
Product Name : Volulyte
Product Type : Carbohydrate
Upfront Cash : Inapplicable
September 11, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
HES 130 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Postoperative Acute Kidney Injury.
Lead Product(s): HES 130,Hydroxyethyl Starch
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Fresenius Kabi AB Brunna
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 16, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HES 130,Hydroxyethyl Starch
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Fresenius Kabi AB Brunna
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients
Details : HES 130 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Postoperative Acute Kidney Injury.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 16, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.
Lead Product(s): Hydroxyethyl Starch,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Carbohydrate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxyethyl Starch,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
March 14, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Hydroxyethyl Starch,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Carbohydrate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 17, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxyethyl Starch,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac S...
Details : Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
August 17, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Blood Pressure Disorders.
Lead Product(s): Hydroxyethyl Starch,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Carbohydrate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 23, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxyethyl Starch,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of HES 130 in Balanced and in Unbalanced Solution
Details : Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Blood Pressure Disorders.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
February 23, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypovolemia.
Lead Product(s): Hydroxyethyl Starch,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Carbohydrate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 21, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydroxyethyl Starch,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypovolemia.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
May 21, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 9005-27-0
End Use API : Hydroxyethyl Starch
About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
47
PharmaCompass offers a list of Hydroxyethyl Starch API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Hydroxyethyl Starch manufacturer or Hydroxyethyl Starch supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hydroxyethyl Starch manufacturer or Hydroxyethyl Starch supplier.
A Hydroxyethyl Starch manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hydroxyethyl Starch, including repackagers and relabelers. The FDA regulates Hydroxyethyl Starch manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hydroxyethyl Starch API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Hydroxyethyl Starch manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Hydroxyethyl Starch supplier is an individual or a company that provides Hydroxyethyl Starch active pharmaceutical ingredient (API) or Hydroxyethyl Starch finished formulations upon request. The Hydroxyethyl Starch suppliers may include Hydroxyethyl Starch API manufacturers, exporters, distributors and traders.
click here to find a list of Hydroxyethyl Starch suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Hydroxyethyl Starch Drug Master File in Korea (Hydroxyethyl Starch KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Hydroxyethyl Starch. The MFDS reviews the Hydroxyethyl Starch KDMF as part of the drug registration process and uses the information provided in the Hydroxyethyl Starch KDMF to evaluate the safety and efficacy of the drug.
After submitting a Hydroxyethyl Starch KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Hydroxyethyl Starch API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Hydroxyethyl Starch suppliers with KDMF on PharmaCompass.
A Hydroxyethyl Starch CEP of the European Pharmacopoeia monograph is often referred to as a Hydroxyethyl Starch Certificate of Suitability (COS). The purpose of a Hydroxyethyl Starch CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hydroxyethyl Starch EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hydroxyethyl Starch to their clients by showing that a Hydroxyethyl Starch CEP has been issued for it. The manufacturer submits a Hydroxyethyl Starch CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hydroxyethyl Starch CEP holder for the record. Additionally, the data presented in the Hydroxyethyl Starch CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hydroxyethyl Starch DMF.
A Hydroxyethyl Starch CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hydroxyethyl Starch CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Hydroxyethyl Starch suppliers with CEP (COS) on PharmaCompass.
Hydroxyethyl Starch Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hydroxyethyl Starch GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Hydroxyethyl Starch GMP manufacturer or Hydroxyethyl Starch GMP API supplier for your needs.
A Hydroxyethyl Starch CoA (Certificate of Analysis) is a formal document that attests to Hydroxyethyl Starch's compliance with Hydroxyethyl Starch specifications and serves as a tool for batch-level quality control.
Hydroxyethyl Starch CoA mostly includes findings from lab analyses of a specific batch. For each Hydroxyethyl Starch CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hydroxyethyl Starch may be tested according to a variety of international standards, such as European Pharmacopoeia (Hydroxyethyl Starch EP), Hydroxyethyl Starch JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hydroxyethyl Starch USP).